Whitehawk Therapeutics (NASDAQ:WHWK) Posts Earnings Results, Beats Expectations By $0.04 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) announced its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04, FiscalAI reports.

Whitehawk Therapeutics Stock Up 0.8%

Whitehawk Therapeutics stock opened at $3.97 on Friday. The stock has a market cap of $196.24 million, a P/E ratio of -2.36 and a beta of 0.70. Whitehawk Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.48. The company’s 50-day moving average price is $3.75 and its two-hundred day moving average price is $2.96.

Insider Buying and Selling at Whitehawk Therapeutics

In other Whitehawk Therapeutics news, CFO Scott M. Giacobello sold 141,600 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $4.13, for a total value of $584,808.00. Following the transaction, the chief financial officer directly owned 295,224 shares of the company’s stock, valued at $1,219,275.12. This represents a 32.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David James Lennon sold 102,395 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $3.51, for a total transaction of $359,406.45. Following the completion of the transaction, the chief executive officer directly owned 691,154 shares in the company, valued at approximately $2,425,950.54. This represents a 12.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 705,358 shares of company stock valued at $2,584,564 in the last three months. 49.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. KVP Capital Advisors LP bought a new position in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $5,242,000. Quadrature Capital Ltd bought a new position in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $28,000. Eversept Partners LP bought a new position in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $630,000. ADAR1 Capital Management LLC bought a new position in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $188,000. Finally, Marshall Wace LLP bought a new position in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $164,000. 52.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

WHWK has been the topic of a number of analyst reports. Oppenheimer reiterated an “outperform” rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research note on Friday. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Citizens Jmp began coverage on shares of Whitehawk Therapeutics in a report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 target price on the stock. Citigroup began coverage on shares of Whitehawk Therapeutics in a report on Thursday, April 16th. They issued an “outperform” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.